Showing results (91-100 of 140) with videos related to

Sort By:
Pageof 14
The Oncologist|March 13, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA TrialSara A Hurvitz, Anthony Gonçalves, Hope S Rugo, et al.
Breast Cancer Research and Treatment|October 9, 2013
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapySara A Hurvitz, Florence Dalenc, Mario Campone, et al.
JCO Oncology Practice|June 25, 2025
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Hope S Rugo, Mina S Sedrak, et al.
Cancer Discovery|October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup AnalysisGuy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
NPJ Breast Cancer|June 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysisLisa A Carey, Delphine Loirat, Kevin Punie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast CancerJoanne L Blum, A Douglas Laird, Jennifer K Litton, et al.
The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.
The Lancet. Oncology|May 8, 2025
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a studySantiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast CancerParvin F Peddi, Peter A Fasching, Duan Liu, et al.
Pageof 14